FDA broadens authorization for Akili’s video game for ADHD

The FDA has broad­ened the la­bel for Ak­ili’s pre­scrip­tion video game to treat pe­di­atric AD­HD as the com­pa­ny re­tools with a new over-the-counter fo­cus.

En­deav­or­Rx be­came the first video game to win FDA au­tho­riza­tion as a men­tal health treat­ment in 2020. While the game was ini­tial­ly launched as an al­ter­na­tive to tra­di­tion­al AD­HD treat­ment for kids 8 to 12 years old, reg­u­la­tors have now ex­pand­ed the au­tho­riza­tion to in­clude teenagers 13 to 17 years old. Ak­ili says the new la­bel should “more than dou­ble” the num­ber of chil­dren el­i­gi­ble for a pre­scrip­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.